Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205529 | 0.98 | SIGMAR1 (0.55) | SIGMAR1CHRNB2CHRNA4MAPTCYP11B1 | |
| SCHEMBL3414893 | 0.94 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4MAPTKDM4E | |
| SCHEMBL2432002 | 0.85 | — | — | |
| SCHEMBL7020285 | 0.84 | SIGMAR1 (0.57) | SIGMAR1CHRNB2CHRNA4MAPTCYP11B1 | |
| Hydrochloric Acid SCHEMBL16600475 | 0.83 | CHRNB2 (0.55) | SIGMAR1CHRNB2CHRNA4MAPTCHRNA7 | |
| Hydrochloric Acid SCHEMBL18230043 | 0.83 | CHRNB2 (0.55) | SIGMAR1CHRNB2CHRNA4MAPTCHRNA7 | |
| Bromide SCHEMBL8686784 | 0.83 | CHRNB2 (0.55) | SIGMAR1CHRNB2CHRNA4MAPTCHRNA7 | |
| Bromide SCHEMBL8691876 | 0.83 | CHRNB2 (0.55) | SIGMAR1CHRNB2CHRNA4MAPTCHRNA7 | |
| SCHEMBL987978 | 0.78 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4MAPTCYP11B1 | |
| SCHEMBL29597435 | 0.78 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4MAPTCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11001698-B2 | Stabilizer composition | BASF SE | 2021-05-11 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10683256-B2 | Process for preparing substituted biphenyls | BASF SE (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20200048431-A1 | STABILIZER COMPOSITION | BASF SE (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048394-A1 | HARDENABLE POLYMER COMPOSITION | BASF SE (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20190210954-A1 | Process for Preparing Substituted Biphenyls | LIANHE CHEMICAL TECHNOLOGY CO., LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| EP-1051415-B1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6495542-B1 | SUCH AS 2-METHOXY-N-(2-METHYL-1H-BENZIMIDAZOL-4-YL)-4-(2,3,4,5-TETRAHYDRO-5-OXO-1H-1-BENZAZEPIN-1-YL)CARBONYL-BENZAM IDE; HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1051415-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037637-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683256-B2 | Process for preparing substituted biphenyls | PIK3CA, PIK3CB, PIK3CG | SIGMAR1 832/4885CHRNB2 2725/4885CHRNA4 2288/4885 |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | SIGMAR1 1003/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | SIGMAR1 1003/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | SIGMAR1 1124/4885CHRNB2 746/4885CHRNA4 1556/4885 |
| US-20190210954-A1 | Process for Preparing Substituted Biphenyls | PIK3CA, PIK3CB, PIK3CG | SIGMAR1 832/4885CHRNB2 2725/4885CHRNA4 2288/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | SIGMAR1 1003/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | SIGMAR1 759/4885CHRNB2 522/4885CHRNA4 1314/4885 |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | SIGMAR1 1003/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | SIGMAR1 1003/4885CHRNB2 2785/4885CHRNA4 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.